GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY21 results · Oct–Dec 2020
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹857.20 crore (up 10.1% from Q3 FY20) and net profit of ₹156.51 crore for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 857.20 | 778.59 | +10.1% | 879.32 | −2.5% |
| Other income | 14.02 | 16.50 | −15.0% | 9.04 | +55.1% |
| Total income | 871.22 | 795.09 | +9.6% | 888.36 | −1.9% |
| Profit before tax | 211.41 | (634.32) | Turned profit | 126.93 | +66.6% |
| Net profit for the period | 156.51 | (661.16) | Turned profit | 76.47 | +104.7% |
| EPS, basic (₹) | 9.24 | (39.03) | Turned profit | 4.51 | +104.9% |
| Net margin (%) | 18.3 | -84.9 | 8.7 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 858.42 | 778.68 | +10.2% | 879.39 | −2.4% |
| Other income | 13.87 | 16.25 | −14.6% | 8.92 | +55.5% |
| Total income | 872.29 | 794.93 | +9.7% | 888.31 | −1.8% |
| Profit before tax | 212.54 | (617.31) | Turned profit | 126.97 | +67.4% |
| Net profit for the period | 157.35 | (644.14) | Turned profit | 76.50 | +105.7% |
| EPS, basic (₹) | 9.29 | (38.02) | Turned profit | 4.52 | +105.5% |
| Net margin (%) | 18.3 | -82.7 | 8.7 |
Consolidated
- Filed with BSE
- 05 Feb 2021, 19:14 IST
- Board meeting
- 05 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Feb 2021, 19:14 IST
- Board meeting
- 05 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE